Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2023 Nov 14;330(18):1795-1797.
doi: 10.1001/jama.2023.19574.

Risk of Gastrointestinal Adverse Events Associated With Glucagon-Like Peptide-1 Receptor Agonists for Weight Loss

Mohit Sodhi  1 , Ramin Rezaeianzadeh  1 , Abbas Kezouh  2 , Mahyar Etminan  3
Affiliations

Risk of Gastrointestinal Adverse Events Associated With Glucagon-Like Peptide-1 Receptor Agonists for Weight Loss

Mohit Sodhi et al. JAMA. .
No abstract available

Plain language summary

This database study examines the association between glucagon-like peptide 1 agonists (eg, semaglutide, liraglutide) used for weight loss and reports of gastrointestinal adverse events.

PubMed Disclaimer

Conflict of interest statement

Conflict of Interest Disclosures: None reported.

Comment in

References

    1. Sauer N, Reining F, Schulze Zur Wiesch C, Burkhardt T, Aberle J. Off-label antiobesity treatment in patients without diabetes with GLP-1 agonists in clinical practice. Horm Metab Res. 2015;47(8):560-564. - PubMed
    1. Rubino DM, Greenway FL, Khalid U, et al. ; STEP 8 Investigators . Effect of weekly subcutaneous semaglutide vs daily liraglutide on body weight in adults with overweight or obesity without diabetes: the STEP 8 randomized clinical trial. JAMA. 2022;327(2):138-150. doi: 10.1001/jama.2021.23619 - DOI - PMC - PubMed
    1. Singh S, Chang HY, Richards TM, Weiner JP, Clark JM, Segal JB. Glucagonlike peptide 1–based therapies and risk of hospitalization for acute pancreatitis in type 2 diabetes mellitus: a population-based matched case-control study. JAMA Intern Med. 2013;173(7):534-539. doi: 10.1001/jamainternmed.2013.2720 - DOI - PubMed
    1. Gudin B, Ladhari C, Robin P, et al. Incretin-based drugs and intestinal obstruction: a pharmacovigilance study. Therapie. 2020;75(6):641-647. doi: 10.1016/j.therap.2020.02.024 - DOI - PubMed
    1. Kalas MA, Galura GM, McCallum RW. Medication-induced gastroparesis: a case report. J Investig Med High Impact Case Rep. 2021;9:23247096211051919. - PMC - PubMed

MeSH terms